We are live on ! Find out more
KBIO

KaloBios Pharmaceuticals
KBIO

Delisted

KBIO was delisted on the 16th of December, 2015.

43 hedge funds and large institutions have $39.8M invested in KaloBios Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

10% less funds holding

Funds holding: 48 → 43 (-5)

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

54% less capital inflows, than outflows

Capital inflows: $4.72M | Capital outflows: $10.2M

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
11
Reduced
14
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KBIO Hedge Fund Activity: Q2 2014 in Review

43 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in KaloBios Pharmaceuticals (KBIO) for Q2 2014, worth a combined $39.8M — down 24% from $52.2M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of KBIO and 13 opened new positions — a net loss of 5 holders — while 14 trimmed existing stakes and 11 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $2.49M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $4.59M sold.

  • 43 institutional investors held KaloBios Pharmaceuticals (KBIO) as of Q2 2014, down from 48 in Q1 2014.
  • Funds reported $39.8M of KaloBios Pharmaceuticals stock for Q2 2014, down 24% quarter-over-quarter.
  • 13 funds opened new KaloBios Pharmaceuticals positions in Q2 2014 and 18 closed out, a net change of -5 holders.
  • The largest KaloBios Pharmaceuticals buyer in Q2 2014 was BVF Inc, an estimated $2.49M added.
  • The largest KaloBios Pharmaceuticals seller in Q2 2014 was JP Morgan Chase, an estimated $4.59M sold.

Based on aggregated 13F filings for Q2 2014.